ViiV Healthcare, a GlaxoSmithKline subsidiary, announced that the FDA has granted its injectable cabotegravir breakthrough therapy designation to prevent HIV. The status was granted based on data from a Phase IIb/III trial that showed cabotegravir being 66% more effective than the oral combo of emtricitabine, tenofovir disoproxil fumarate for HIV prevention.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information
that is changing your industry today, hand-curated by our professional editors from
thousands of sources and delivered straight to your inbox.